DDrare: Database of Drug Development for Rare Diseases

88. 慢性血栓塞栓性肺高血圧症
［臨床試験数：145，薬物数：112（DrugBank：22），標的遺伝子数：13，標的パスウェイ数：52］

Searched query = "Chronic thromboembolic pulmonary hypertension", "CTEPH", "Idiopathic chronic pulmonary thromboembolism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-ACETATE; 11C-acetate; ACT-064992; ACT-293987; AMBRISENTAN; Acetate; Adempas; Adempas (Riociguat, BAY63-2521); Adempas®; Ambrisentan; Ambrisentan 5 mg; Ammonia; Atorvastatin; BARNASCAN; BAY 63-2521; BAY 63-2521 IR coated tablet 1.0 mg; BAY 63-2521 IR coated tablet 1.5 mg; BAY 63-2521 IR coated tablet 2.0 mg; BAY 63-2521 IR coated tablet 2.5 mg; BAY 63-2521 IR tablet 0.5 mg; BAY 63-2521 IR tablet 1.0 mg; BAY 63-2521 IR tablet 1.5 mg; BAY 63-2521 IR tablet 2.0 mg; BAY 63-2521 IR tablet 2.5 mg; BAY 63-2521 coated tablets 0.5 mg; BAY 63-2521 coated tablets 1 mg; BAY 63-2521 coated tablets 1.5 mg; BAY 63-2521 coated tablets 2 mg; BAY 63-2521 coated tablets 2.5 mg; BAY 63-2521 tablets 0.5 mg; BAY 63-2521 tablets 1 mg; BAY 63-2521 tablets 1.5 mg; BAY 63-2521 tablets 2 mg; BAY 63-2521 tablets 2.5 mg; BAY1237592; BOSENTAN; BPA; Barnascan; Behavioral: respiratory and exercise therapy; Behavioral: respiratory and exercise therapy with supplemental oxygen; Bosentan; Bosentan monohydrate; Cysteine; D-glucose; Diagnostic Test: Endogenous thrombin potential; Diagnostic Test: Light transmission aggregometry; Diagnostic Test: Platelet function analyzer-100; Diagnostic Test: Rotational thromboelastometry; Edoxaban; FLUDEOXYGLUCOSE; Fludeoxyglucose; GSK1325760; Glucose; Imatinib; Imatinib mesilate; Iodine; JNJ-67896062 / ACT-064992; MACITENTAN; Macitentan; Macitentan 10 mg; Macitentan tablets; Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb; Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth; MultiHance; N-acetyl cysteine; NS-304; NS-304 Placebo; OXYGEN; Opsumit; Opsumit®; Oxygen; Oxygen, liquid; PH-combination therapy; PH-monotherapy; Placebo; Procedure: Ballon Pulmonary Angioplasty; Procedure: Balloon Pulmonary Angioplasty (BPA); Procedure: NO gas; Procedure: Pulmonary Endarteriectomy; Procedure: Pulmonary endarterectomy; Procedure: Supplemental oxygen via a mask; Procedure: long term oxygen therapy; RIOCIGUAT; Radiation: Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3); Radiation: Computed tomography lung subtraction iodine mapping; Remodulin; Remodulin (R); Remodulin 10mg/ml 20ml; Remodulin 1mg/ml 20ml; Remodulin 2.5mg/ml 20ml; Remodulin 5mg/ml 20ml; Riociguat; Riociguat (ADEMPAS, BAY63-2521); Riociguat (Adempas, BAY63-2521); Riociguat Oral Tablet; Ro 47-0203; SELEXIPAG; Sauerstoff; Selexipag; TRACLEER; TRACLEER 125MG 56CPR RIV.; TRACLEER*56CPR RIV 125MG; TREPROSTINIL SODIUM; Thrombin; Tracleer; Treprostinil; Treprostinil Sodium; Treprostinil sodium; Uptravi; Volibris; Warfarin; [18F]Fluoro-2-deoxy-2-D-glucose

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-006441-10-DE (EUCTR)	27/05/2010	28/01/2010	Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension	Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension	Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension	Trade Name: Remodulin 1mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM Trade Name: Remodulin 2.5mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM Trade Name: Remodulin 5mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM Trade Name: Remodulin 10mg/ml 20ml Other descriptive name: TREPROSTINIL SODIUM	MRN-Medical Research Network GmbH	NULL	Not Recruiting			Female: yes Male: yes	100		Czech Republic;Germany;Austria

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2008-006441-10-DE
(EUCTR)

27/05/2010

28/01/2010

Double Blind Controlled Clinical Investigation into the Efficacy and Tolerability of subcutaneously administered Treprostinil Sodium in Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension

Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension

Trade Name: Remodulin 1mg/ml 20ml
Other descriptive name: TREPROSTINIL SODIUM
Trade Name: Remodulin 2.5mg/ml 20ml
Other descriptive name: TREPROSTINIL SODIUM
Trade Name: Remodulin 5mg/ml 20ml
Other descriptive name: TREPROSTINIL SODIUM
Trade Name: Remodulin 10mg/ml 20ml
Other descriptive name: TREPROSTINIL SODIUM

MRN-Medical Research Network GmbH

NULL

Not Recruiting

Female: yes
Male: yes

100

Czech Republic;Germany;Austria